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 SUMMARY 
 
We report the case of a yolk sac tumor of the ovary in a 26 
years old woman. The laparoscopic approach and the BEP 
chemotherapy were fundamental to have a minimally 
invasive treatment and to preserve fertility. 
 





The  ovarian germ cell tumors (OGCTs) [tab.1] represent 
15-20% of all ovarian tumors [1] and originate from the 
primitive germ cell and then gradually differentiate to 
mimic the developmental tissues of embryonic origin 
(ectoderm, mesoderm,endoderm), and the extraembryonic 
tissues (yolk sac and trophoblast). Malignant Ovarian 
germ cell tumors (MOGCTs) constitute 3-5% of all 
ovarian malignancies [2,3]. OGCTs are subdivided into 
germinomatous e non-germinomatous tumors. The most 
common types of non-germinomatous tumors are yolk sac 
and immature teratoma. As regard as ovarian yolk sac 
tumors (YST) altough rare, are the second most frequent 
histological subtype of MOGCTs , after ovarian 
dysgerminoma. They account for 20% of MOGCTs [4] 
and are frequent especially in childhood and in  early 
adulthood, between 18-30 years old woman[5]. For this 
reason the treatment of yolk sac tumors is finalized to 
preserve the fertility and therefore it is imperative that 
these tumors are managed with accurate diagnosis, staging 
and treatment. 
We report here the case of a 26 years old women with a 




A 26 years old female with body height of 1,68 m  was 
admitted to our department with abdominal pain. She 
referred us a history of intermittent abdominal pain which 
had slowly been worsening over three month. In the last 
month there was loss of appetite. She reported amenorrhea 
for the past two cycles. She had no important past medical 
or surgical history. On palpation a vague mass was felt in 
the lower abdomen. The vaginal examination revealed a 
mass in the left fornix that was mobile and sore. 
After the visit we executed an ultrasound examination 
with 3.5 MHz curvilinear probe that revealed a large mix 
echogenic mass measuring approximately 4cm in mayor 
diameter and 2,5 cm in smaller arising from pelvis that 
appears multilocular, cystic and solid in nature. At color 
doppler examination there was increased vascularity noted 
in the solid component of mass. No evidence of 
calcification. No fluid in the Douglas. The origin of the 
mass could not be ascertained, but was felt to be likely 
from the left ovary because a separate, normal left ovary 
could not be visualized. The right ovary appeared 
normally with the presence of a follicle of 1,5 cm. 
Biochemical and laboratory investigations were made. 
Labs included a hemoglobin of 12,1 g/dl, a hematocrit of 
37,9% and platelets of 275.000; creatinine was normal 
(0,76 mg/dl) and also BUN (32 mg/dl); liver function tests 
that included bilirubin (0,54 mg/dl), aspartate 
aminotrasferase (19 u/L), alanine aminotrasferase (17 u/L) 
were normal; Serum human gonadotropin hormone levels 
(4,2 mUI/ml) and CA-125 levels (293 UI/L) were within 
normal limits. A markedly elevated serum alpha-
fetoprotein (AFP) level to 18.178 ng/ml oriented toward 
the diagnosis of an ovarian yolk sac tumor.  
Subsequently, CT of the abdomen was performed. A 4,5 
cm size complex mass lesion in the left ovary with solid 
component and cystic areas adjacent to it was present. 
Pelvic and paraahortic lymph nodes were in the range 
limits for the dimension and morphology. No calcified 
peritoneal implants were apparent, the others abdomen 
bowels appeared of normal structure. 
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After our evaluations we decided to plan a laparoscopic 
surgery. We provide the steps of surgery;  after the 
creation of pneumoperitoneum with Verres needle, a 
central trocar was used for the optics, others three trocars 
were inserted as lateral operative accesses.The uterus and 
right adnexa  appeared normal with no lesion; the left 
adnexa showed a large mass with cystic and necrotic 
aspects. There was no peritoneal carcinomatosis and no 
lesions on the liver or subdiaphragmatic areas. A 
peritoneal washing was made; After a total omentectomy, 
obturator and paraahortic lymph nodes dissection were 
also added to the left salpingo-oophorectomy; a biopsy of 
right ovary, of left parieto- colic sulcus and 
appendicectomy were made. Specimens were sent for 
histopathological examination [Tab2]. The left ovary mass 
showed tumor cells arranged in papillary groups with a 
glandular pattern and acinar structure. The lining of the 
papillary infolding was irregular. Also there was the 
presence of Schiller-Duvall body, typical patterns of YST. 
The postoperative course was regular and the alpha-
fetoprotein levels decreased rapidly. It was planned a 
chemotherapy with the BEP regimen (Bleomycin, 
Etoposide, Cisplatin). A total  of two cycles of 
chemotherapy were repeated every 3 weeks. Serum AFP 




Yolk sac tumor is also called endodermal sinus tumor 
(EST) because there is a link to its discovery. 
Histologically the malignant tissue resemble structure 
found in early embryonic development, and it is Shiller’s 
stressing of the unique glomeruloid structure that led 
Telium to compare it with the yolk sac endodermal 
sinuses of Duval in the rat placenta[6]. 
High values of AFP orientate strongly to diagnosis of 
YST. Furthermore it is a sensible marker for tumor’s 
evolution; infact a rapid decrease of AFP levels in the 
serum after surgery is a sign of  absence of residual tumor. 
Also the efficiency of chemotherapy its related with 
normalization of AFP [8].  It is almost always unilateral 
and large with a diameter that may vary from 5 to 50 cm 
(median 15 to 19 cm)[9]. The typical neoplasm manifest 
as a large complex pelvic mass that extends into the 
abdomen. This tumor is often characterized by extremely 
rapid growth and extensive intra-abdominal spreading 
with poor prognosis [10]. 
As regard clinical, abdominal pain is the principal 
symptom leading the discovery of the disease which may 
require the emergency surgery especially in cases of 
ovarian torsion [11]. Other  symptoms are the presence of 
an abdominal or pelvic mass with abdominal enlargement, 
vaginal bleeding, fever, ascites or peritonitis secondary to  
torsion, infection or rupture of the ovarian tumor[3, 8].In 
consequence of ascites it’s possible to have decrease 
breath sounds in the bilateral lung bases, diffuse 
tenderness to palpation of the abdomen and distant bowel 
sound [12]. 
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Table2: pathologist report, Department of Pathology; 
University of Salerno, Salerno,Italy. 
 
Preoperative radiological diagnosis is difficult. Yolk sac 
tumors can be cystic, with signs of hypervascularization 
and areas of haemorrhage. However YST haven’t a 
specific image both ultrasound that  MRI and CT . If YST 
appear with a solid portion, multiple small arterioles with 
lower RI are detectable by color Doppler ultrasound, 
haemorrhagic spots can be demonstrated by T1 weighted 
MRI, hypervascularity can be shown on contrast-enhanced 
T1 weighted scans [7]. The malignant evolution of YST 
consist in locoregional extension involving uterus, pelvic 
peritoneum,rectum and bladder. Other authors described 
the involvement of the omentum, abdominal peritoneum 
and serosal surfaces of bowel in 30% of the cases. 
Retroperitoneal lymph nodes and liver parenchyma were 
also involved in advanced stages.[3, 13, 14] 
The standard management of malignant ovarian germ cell 
tumors is complete surgical excision. 
Because of most of them are unilateral, it’s possible 
executing a fertility sparing surgical treatment. The type 
of surgical procedure was not an important prognostic 
factor for patients with malignant germ cell tumors of the 
ovary at all clinical stages, and so the conservative surgery 
is possible if it’s followed by chemotherapy[15]. 
In the past after the laparoscopic diagnosis of an ovarian 
cancer, laparo-conversion was recommended to have an 
optimal staging and to avoid an uncertain tumor cell 
spread. Today, advancement in technologies offers a 
minimally invasive surgery that recognizes in the 
laparoscopic surgery a new approach for ovarian cancer. It 
gave us not only a same or even better surgical prognosis 
as compared the conventional laparotomy[16] but benefit 
from a less traumatic surgery and a potentially faster 
recovery[17]. 
 
The aim of surgery is removing the primary ovarian tumor 
without excessive morbidity. Thus cycles of 
chemotherapy should be administer while monitoring the 
rate of decline of serum  AFP. Specifically,  before the 
introduction of effective combination chemotherapy, the 
prognosis for patients with malignant non-
dysgerminomatous cancers   was poor; as regards patients 
with YST, they  had a 3-year survival rate of 13% [18]. 
Currently, initial surgery followed by adjuvant 
chemotherapy including bleomycin, etoposide and 
cisplatin (BEP) is considered the standard for the 
treatment of  YolkSacTumor [19].  
Compared with other regimens, BEP appears to be the 
best active first-line option for primary, metastatic, or 
recurrent disease. As regards the chemotherapy-related 
toxicity, it   was acceptable and severe collateral effects 
was infrequent, although myelosuppression can be 
observed in the majority of patients. The administration of 
G-CSF would help manage this toxicity. Infrequent severe 
pulmonary toxicity, ototoxicity, or nephrotoxicity are 
observed [20]. 
Administration of bleomycin as a slow infusion (over 24 
h)may reduce the incidence of toxicity, but this has yet to 
be confirmed [19]. Administration of etoposide for three 
days instead of five, is an effort to decrease the incidence 
of neutropenia without sacrificing efficacy. Etoposide has 
been reported to be associated with the development of an 
acute leukemia with typical morphological and 
cytogenetic features [22].  Long-term toxicity was limited 
and consisted in hypertension, as already described in 
testicular cancer survivors [21-23]. 
Progressive or recurrent ovarian YST after treatment with 
BEP chemotherapy is associated with a poor prognosis. 
There are not approved schemes of chemotherapy in this 
cases, so it is possible adapt chemotherapy used for 
recidivist testicular cancer. Possible options of 
chemotherapy include combination of vinblastine, 
ifosfamide, cisplatinum, or paclitaxel, ifosfamide, 
cisplatinum, [24].  It should also be stressed that 
secondary cytoreductive surgery could play an important 
role when tumors are limited and resistant to 
chemotherapy. 
As regards the follow-up of chemotherapy, the 
determination of initially elevated markers (AFP) should 
be repeated before each cycle of therapy, soon after the 
end of the treatment and during the 2 years after the end of 
chemotherapy[20]. An annual pelvic ultrasound is 
necessary in the case of conservative treatment, to screen 
for a contralateral recurrence[25].  
The BEP regimen, no ascites at presentation, stage I 
disease, less of 42 days to AFP normalization, fertility-
sparing surgery and a serum AFP half-life less of 10 days 
are factors associated with a good prognosis. 
Lumbaraortic lymphadenectomy has been proposed to 




Left ovary with 
mass (4,5 cm * 2 
cm) + left 
fallopian tube (6 
cm) 
Residual ovarian parenchyma 
and cystic spaces lined by cells 
with clear cytoplasm and 
hyperchromatic nuclei arranged 
in papillary groups compatible 
with yolk sac tumor 
Appendix (3 cm) Absence of disease 
Omentum  with 
free areas of 
thickening (12 cm 
* 4 cm) + left 
parieto-colic 
sulcus (1,5 cm) 
Absence of disease 
Right ovary 
biopsy  
Ovarian parenchyma with 




Reactive hyperplasia  
9 obturator lymph 
nodes 
Reactive hyperplasia 
Peritoneal fluid Inflammatory and mesothelial 
cells, absence of malignant cells. 
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in order to guide the choice of adjuvant chemotherapy 
[25]. 
In the study of de La Motte, Rouge and collaborators [4] 
lymphnode metastasis was found exclusively in 2 patients 
with stage IIIC peritoneal disease in whom chemotherapy 
is mandatory. No lymph node involvement was found in 
stage I disease. 
Another important consideration is the impact of 
chemotherapy on gonadal and reproductive function. In 
the past the majority of patients  with MOGCT receiving 
multidrug  combination chemotherapy, showed  a 
decreased number of primordial follicles and an increase 
in stromal fibrosis and in atrophied cortices [26]. Today 
for early stage disease the aim of chemotherapy is to be 
efficacy and at the same time to minimize toxicity and 
retain reproductive function [27, 28].  Different studies 
[29, 30] reported the resume of normal menstrual function 
and in some patients pregnancies after BEP 
chemotherapy. For example, Brewer et al reported on 26 
patients treated with BEP for MOGCT, 71% of which 
resumed normal menstrual function, and six of whom 
conceived[29].  
 
Therefore  the risk of of infertility following treatment of 
MOGCT is always a concern, even if the majority of 
patients, especially in the early stage, will maintain their 
ovarian function and fertility. Following this strategy, 
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